1. Revenues for the quarter stood at ₹332 Cr (7% growth YoY).
2. EBITDA for the quarter was at ₹122 Cr (13.5% growth YoY). EBITDA margin for the quarter was at 37%. PAT for the quarter was ₹101 Cr (12% growth YoY)
3. The Guwahati facility contributed to 80% of the revenues for the quarter. Operating cash flow to EBITDA stood at 73% for the 9 months.
4. The growth has been driven by sustained market leading performance in all the top 5 therapies - Diabetes, Cardiology, VMN, CNS and Women's health which collectively account for 91% of revenues.
5. They have entered into the insulin analogues and GLP1 markets through a joint venture with MJ Biopharm in which Eris holds a 70% equity stake. They are on track to launch human insulin next month.
6. They are creating a new division with 140 medical representatives to kick start the insulin business. The next big product from this joint venture would be Glargine which is presently in phase 3 clinical trials and is expected to launch sometime in calendar year 2023.
7. The MR productivity has increased to ₹5.1 lakhs from ₹4.6 lakhs in Q3 FY21. This has contributed significantly to increasing the EBITDA margin from 36% to 37.3% in the first 9 months of FY22.
8. Of the 10 new launches planned for this financial year, they have launched 4 in the first 9 months. They have several more launches lined up in Q4 including Human Insulin and Drolute, which is their brand of Dydrogesterone in the Women's Health segment.
9. Dydrogesterone is a synthetic progestogen that is used to treat hormonal disorders in women. This is a 500+ crore market which is growing in excess of 40% per annum.
10. When evaluating new acquisitions they have to consider that their standalone gross margins are 84%, so anything below 70-75% gross margin is not feasible for them.
11. The entire oral anti-diabetes therapy is being taken over by the DPP4s and SGLT2s at a very rapid rate. If you exclude these products, there is no growth in the entire oral anti-diabetes market.
12. There is a dip in chronic therapies for 2 reasons - first one is, whenever the acute therapy becomes very heavy, the overall stocking on chronic therapies goes down
and the second reason is patients with chronic diseases stocked up on medicines during the initial COVID outbreak and the demand has not normalized yet.
13. In the diabetes segment, they understand that Glimepiride is no longer a first line of treatment and they have been moving towards the combination drug Glimisave MV which has become the No. 2 drug in its category. It did sales of about ₹80-84 Cr and is growing at 15%.
14. They have launched Dydrogesterone and expect ₹6 Cr run rate this quarter. They are expecting revenues of ₹30 Cr next year and ₹50 Cr in 2 years.
15. The only player who has taken a lead in the online pharmacy space is PharmEasy. Overall organized pharma retail accounts for about 3.5% penetration of the IPM and they receive no discounts.
16. The company is developing a very symbiotic relationship with these players as they are able to provide very insightful pin code level data.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
1. The revenue for Q3 was 107 cr up by 13.7% QoQ an 37.7% YoY
2. EBITDA stood at 32.2 cr for Q3 and EBITDA margins stood at 29.9%, giving the industry highest margins.
3. PAT for Q3 was 49.9 cr and PAT margins stood at 44.2%
4. Technology sector contributes around 67% of revenues
5. CPG Contributes 15% of the revenues and other contribute around 18% of revenue.
6. 6 clients were added in this quarter
7. Utilisation stands around 80% - 85%
Business Updates-
1. Latent View Analytics is a pure play Analytics company and also little towards consulting and data engineering, Business analytics is 60% of the business.
1. The revenue for the quarter was 120 cr up by 9% QoQ
2. EBITDA stood at Rs 187 million vs Rs 137 million in Q3FY21, up by 36.6%
3. PAT was at Rs 116 million vs Rs 125 million in Q3FY21
The 9M revenue stood at 293 cr up by 31.3% compared to same period last year
The 9M PAT was up by 12.3%
4. Net cash position stood at 163 cr
Business Updates -
1. The company sees demand and traction also on the renewal side
ER&D business did well in the year 2021 and also the Aerospace business did well.
1. Revenues for the quarter stood at ₹2510 Cr (46% growth YoY).
2. PBT for the quarter stood at ₹1034 Cr (61% growth YoY).
3. Exports contributed to 92% of revenues for the quarter. Europe and the US contributed to 79% of revenues .
4. Generics contributed to 40% and Custom Synthesis contributed to 60% of revenues for the quarter. Nutraceutical business contributed ₹166 Cr for the quarter.
5. They have capitalized ₹196 Cr of capex during the quarter and ₹762 Cr for 9 months. They expect another ₹100 Cr to be capitalized by the end of the financial year. Capex in the new SEZ accounted for ₹368 Cr.
1. Revenues for the quarter stood at ₹796 Cr (5% decline YoY).
2. Gross margins decline by 840 bps YoY.
3. Gross margin compression is due to product mix and they had inventory of increased RM prices which were adjusted to the lower realizations they received.
4. They are seeing an uptick in opportunities in the regulated markets and are expecting to see a sequential recovery from here. They believe that some of the products that they let go due to increased competition is playing in their favor.